New Alert Released Breaking News This Morning

AwesomeStocks Hello! We wanted to update our new alert SXTP, discussing more in-depth the company’s breaking news from this morning. Here is the announcement from this morning: “60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov” Here are the highlights from this press release: - “ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of disease progression, has been registered on ClinicalTrials.gov” - “60P’s majority-owned subsidiary, 60P Australia Pty Ltd, has opened a new IND and will conduct the trial, enrolling patients at U.S. clinics beginning in fourth quarter of 2023” - “Primary endpoint of ACLR8-LR will be time to sustained clinical recovery from COVID-19 symptoms” - “60P was recently awarded a U.S. patent covering tafenoquine for treatment of COVID-19 and other lung infections. Tafenoquine is the active molecule in 60P’s FDA-approved drug for malaria prevention, ARAKODA” - “60P estimates that 25 percent of U.S. population without risk factors for progression to serious COVID is not appropriate for currently marketed, oral treatments – a significant unmet need” “WASHINGTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (“60 Degrees Pharmaceuticals” or “60P”) (NASDAQ: SXTP), a company specializing in developing and marketing medicines for infectious diseases, today announced that ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine the efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of disease progression, is now listed on ClinicalTrials.gov.” As the company further explains: “Public health interest in combating COVID-19 remains high. Currently marketed orally administered COVID-19 therapeutics are not appropriate for use by at least 25 percent of the U.S. population who do not have risk factors for progression to severe disease or by travelers who may wish to protect themselves from COVID-19 for extended periods - an unaddressed multi-billion-dollar market opportunity.” Importantly, as the company states in the press release: “Data from a Phase II study published in New Microbes and New Infections, Vol. 47, April – May 2022, a peer-reviewed, open-access journal, suggested a positive therapeutic signal in mild-moderate COVID-19 disease using the ARAKODA regimen of tafenoquine; the time to clinical recovery from COVID-19 symptoms was accelerated by about 2 – 2.5 days in the tafenoquine arm.” Furthermore: “In April, the United States Patent and Trademark Office (USPTO) issued a patent covering the use of tafenoquine as a treatment for COVID-19 disease. Tafenoquine is the active molecule in 60P’s FDA-approved regimen for malaria prevention, ARAKODA. 60P now owns the exclusive rights for the use of tafenoquine for treatment of lung infections including COVID-19 in the U.S. through 2040.” Here are some of the company’s comments from this press release: “Publicly registering ACLR8-LR represents an important milestone in 60P’s clinical research strategy,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow. “We remain optimistic that results of ACLR8–LR will play an important role in public health efforts to address gaps in the standard of care for COVID-19.” This could be another important growth catalyst for the company. Looking at the chart, SXTP could be positioning for a major bounce opportunity. SXTP has a 20 day moving average of 2.08, more than 25% above today’s open of 1.66. Furthermore, last month SXTP traded as high as 8.65, more than 420% above today’s open. SXTP has a RSI of only 22, suggesting big upside potential. We are continuing to monitor this opportunity. Sources: [WHO]( [CDC]( [PR1]( [PR2]( [PR3]( [PR4]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated twelve thousand five hundred dollars by bank wire transfer on 8/11/23 for the distribution of this advertisement about SXTP dated 8/15/23. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr Orlando Florida 32822 USA [Unsubscribe]( | [Change Subscriber Options](